参考文献/References:
[1]JafariNezhad A,YektaKooshali MH.Lung cancer in idiopathic pulmonary fibrosis:a systematic review and metaanalysis.PLoS One,2018,13(8):e0202360.
[2]Lee HY,Lee J,Lee CH,et al. Risk of cancer incidence in patients with idiopathic pulmonary fibrosis:a nationwide cohort study.Respirology,2021,26(2):180-187.
[3]Samarelli AV,Masciale V,Aramini B,et al.Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development.Int J Mol Sci,2021,22(22):12179.
[4]卢蔷薇,韩闪,刘晓秋.特发性肺纤维化相关的肺癌发病机制的研究进展.中国肺癌杂志,2022,25(11):811-818.
[5]Willis BC,Borok Z.TGFbetainduced EMT:mechanisms and implications for fibrotic lung disease.Am J Physiol Lung Cell Mol Physiol,2007,293(3):L525-L534.
[6]Landskron G,De la Fuente M,Thuwajit P,et al.Chronic inflammation and cytokines in the tumor microenvironment.J Immunol Res,2014,2014:149185.
[7]郭春玉,张诗晨,方军.特发性肺纤维化中氧化应激调控机制的研究进展.安徽医科大学学报,2021,56(6):999-1002.
[8]Nomura K,Fukui M,Hattori A,et al.Diagnostic value of nodal staging of lung cancer with usual interstitial pneumonia using PET.Ann Thorac Surg,2022,114(6):2073-2079.
[9]Porter JC,Ganeshan B,Win T,et al.［18F］FDG PET/CT signal correlates with neoangiogenesis markers in patients with fibrotic interstitial lung disease who underwent lung biopsy:implication for the use of PET/CT in diffuse lung diseases.J Nucl Med,2024,65(4):617-622.
[10]Catelli C,Faccioli E,Silvestrin S,et al.Lung transplantation in patients with previous or unknown oncological disease:evaluation of short and longterm outcomes.Cancers (Basel),2024,16(3):538.
[11]Moldvai D,Sztankovics D,Dankó T,et al.Tumorigenic role of tacrolimus through mTORC1/C2 activation in posttransplant renal cell carcinomas.Br J Cancer,2024,130(7):1119-1130.
[12]Zhou C,Dong X,Chen G,et al.Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC:the randomized doubleblind phase 3 IMpower151 trial.Nat Med,2025,31(7):2375-2384.
[13]Chen S,He Z,Li M,et al.Efficacy and safety of metronomic oral vinorelbine and its combination therapy as second and laterline regimens for advanced nonsmallcell lung cancer:a retrospective analysis.Clin Transl Oncol,2024,26(12):3202-3210.
[14]Sun D,Zhu H,Xu Q,et al.Comparative efficacy of bonemodifying agents in the treatment of lung cancer bone metastases:immunotherapy era.Future Oncol,2025,21(19):2483-2493.